In summary, while our study provides a solid foundation for the development of TRPM4 antagonists as potential therapeutics for neurodegenerative diseases, addressing these limitations through future research will be critical to realizing their full clinical potential. This evidence concerns the gene TRPM4 and neurodegenerative disease.